AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 9316009
Drug: Intravenous carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous carboplatin (CBDCA) with etoposide (Group I)
Trial: 9316009
Drug: Oral etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral etoposide alone (Group II)
Trial: 3875515
Drug: Cetacaine spray
DrugBank: Butamben (DB11148)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cetacaine spray
Trial: 3875515
Drug: Hurricaine spray
RxNorm normalized name: Hurricaine Spray Extension Tube
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hurricaine spray
Trial: 3875515
Drug: 10% Xylocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% Xylocaine spray
Trial: 29971997
Drug: Auricular intradermal
RxNorm normalized name: fluocinolone
DrugBank: Fluocinolone (DB12553)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Auricular intradermal needling combined with erjian (HX6,7i) bloodletting
Trial: 29971997
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of estazolam (1mg each day for 4 weeks)
Trial: 24070810
Drug: Cold compress
RxNorm normalized name: RITE AID Hot & Cold Compress
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cold compress (CC)
Trial: 24070810
Drug: Artificial tears
RxNorm normalized name: Artificial Tears
DrugBank: Polyethylene glycol 400 (DB11077)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artificial tears combined with cold compress (ATs + CC)
Trial: 24070810
Drug: Cold compress
RxNorm normalized name: RITE AID Hot & Cold Compress
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cold compress combined with artificial tears (CC + ATs)
Trial: 24070810
Drug: Cold compress
RxNorm normalized name: RITE AID Hot & Cold Compress
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cold compress combined with epinastine hydrochloride (CC + EH)
Trial: 24070810
Drug: Epinastine hydrochloride
RxNorm normalized name: Epinastine Hydrochloride
DrugBank: Epinastine (DB00751)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Epinastine hydrochloride combined with cold compress (EH + CC)
Trial: 22975501
Drug: OHA 2
RxNorm normalized name: 4-OHAD
DrugBank: Formestane (DB08905)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OHA 2 mg, 4 mg, and 8 mg (single and multiple doses)
Trial: 22975501
Drug: OHA 4
RxNorm normalized name: 4-OHAD
DrugBank: Formestane (DB08905)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OHA 4 mg (fed condition)
Trial: 22975501
Drug: OHA (single-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OHA (single-dose and multiple-dose) in elderly
Trial: 10553738
Drug: Clozapine 600
RxNorm normalized name: clozapine 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clozapine 600 mg/day
Trial: 15951089
Drug: Clozapine with
RxNorm normalized name: Clozapine
DrugBank: Clozapine (DB00363)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clozapine with plasma levels > 150 ng/ml
Trial: 15951089
Drug: Clozapine regardless
RxNorm normalized name: Clozapine
DrugBank: Clozapine (DB00363)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clozapine regardless of dose
Trial: 10066007
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose clomipramine
Trial: 10066007
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose clomipramine
Trial: 24969712
Drug: Routine therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine therapy with HFCWO
Trial: 17405901
Drug: FOLFOX4 plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOLFOX4 plus bevacizumab (10 mg/kg, i.v. infusion on day 1, every 2 weeks)
Trial: 10453433
Drug: Intervention group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention group (187 patients) with systematic lipid assessment and active pharmacologic lipid therapy.
Trial: 2675597
Drug: Strict diabetic
RxNorm normalized name: Diabetic Tussin EX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Strict diabetic protocol (diet and insulin therapy)
Trial: 2675597
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (normal oral glucose tolerance test)
Trial: 322251
Drug: Dissolvent tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dissolvent tablets containing mixed enzyme preparations
Trial: 322251
Drug: Dissolvent tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dissolvent tablets containing pure enzymes
Trial: 322251
Drug: Steradent tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steradent tablets
Trial: 29268061
Drug: Continuous wound
RxNorm normalized name: Uniphyllin Continus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous wound infusion
Trial: 23637967
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg CPG 7909 as adjuvant
Trial: 21991704
Drug: Cooled lignocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cooled lignocaine gel (4 degrees C)
Trial: 21991704
Drug: Room temperature
RxNorm normalized name: ROOM DEODORIZER POWDER MENTOR #3202
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Room temperature lignocaine gel (20 degrees C)
Trial: 10562823
Drug: Chloroquine (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chloroquine (25 mg base/kg body weight over 3 days) + Primaquine (15 mg daily for 14 days)
Trial: 1686131
Drug: Flumazenil 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flumazenil 0.5 mg/h
Trial: 1686131
Drug: Flumazenil 0.1
RxNorm normalized name: flumazenil 0.1 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flumazenil 0.1 mg/h
Trial: 25295719
Drug: PCIA with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCIA with morphine (M group)
Trial: 25295719
Drug: PCIA with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCIA with tramadol combined with lornoxicam (L group)
Trial: 22777991
Drug: Oral ferrous
RxNorm normalized name: ferrous fumarate Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ferrous sulfate (80 mg of elemental iron daily)
Trial: 17563739
Drug: Interleukin 2
RxNorm normalized name: Recombinant interleukin 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interleukin 2 (IL-2) at 1 million units/m² SQ daily for 28 days
Trial: 17563739
Drug: Cyclosporine A
RxNorm normalized name: CycloSPORINE A
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporine A (CsA) at 1.25 mg/kg intravenously daily from day 0 to +28 and interferon gamma (IFN-gamma) 0.025 mg/m² SQ every 2 days from day +7 to +28
Trial: 15712603
Drug: Histamine releasing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Histamine releasing test (HRT) for high suspicion level drugs
Trial: 15712603
Drug: Interferon (INF)-gamma
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon (INF)-gamma releasing test for high suspicion level drugs
Trial: 15712603
Drug: CellScan method
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CellScan method for high suspicion level drugs
Trial: 15712603
Drug: Histamine releasing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Histamine releasing test (HRT) for low suspicion level drugs
Trial: 15712603
Drug: Interferon (INF)-gamma
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon (INF)-gamma releasing test for low suspicion level drugs
Trial: 15712603
Drug: CellScan method
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CellScan method for low suspicion level drugs
Trial: 10097871
Drug: Alternative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alternative treatment options (including psychopharmacology)
Trial: 2403654
Drug: Ceftriaxone (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone (100 mg/kg/day, intravenously once daily; n = 53)
Trial: 2403654
Drug: Cefuroxime (240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefuroxime (240 mg/kg/day, intravenously in four equal doses; n = 53)
Trial: 25442042
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy with oxaliplatin (130 mg/m² on day 1) and capecitabine (1000 mg/m² twice daily for 14 days every 3 weeks), followed by chemoradiation therapy (50 Gy over 5 weeks with modified XELOX regimen), and then consolidation chemotherapy with XELOX regimen.
Trial: 25442042
Drug: Neoadjuvant sandwich
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant sandwich treatment using XELOX regimen as induction, concomitant, and consolidation chemotherapy.
Trial: 19357442
Drug: Doxepin, 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxepin, 10 mg, twice a day for 1 week
Trial: 9839759
Drug: Donepezil HCl
RxNorm normalized name: donepezil HCl
DrugBank: Donepezil (DB00843)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Donepezil HCl 1 mg
Trial: 9839759
Drug: Donepezil HCl
RxNorm normalized name: donepezil HCl
DrugBank: Donepezil (DB00843)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Donepezil HCl 3 mg
Trial: 9839759
Drug: Donepezil HCl
RxNorm normalized name: donepezil HCl
DrugBank: Donepezil (DB00843)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Donepezil HCl 5 mg
Trial: 9839759
Drug: Donepezil HCl
RxNorm normalized name: donepezil HCl
DrugBank: Donepezil (DB00843)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Donepezil HCl (all doses)
Trial: 7806692
Drug: Gepirone (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gepirone (10 mg capsules, thrice daily, up to 120 mg daily)
Trial: 2760597
Drug: Brief dynamic
RxNorm normalized name: water
DrugBank: Water (DB09145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brief dynamic therapy
Trial: 31384338
Drug: Tropisetron (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tropisetron (5 mg IV)
Trial: 23992935
Drug: Icosapent ethyl
RxNorm normalized name: Icosapent Ethyl
DrugBank: Icosapent ethyl (DB08887)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Icosapent ethyl (IPE) 2 g/day
Trial: 20336302
Drug: 0.2 mg
RxNorm normalized name: niacin 0.2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg of tamsulosin daily for 6 months
Trial: 20336302
Drug: Tamsulosin after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamsulosin after cessation of therapy
Trial: 20336302
Drug: Placebo after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo after cessation of therapy
Trial: 11917292
Drug: Pharmacologic agents
RxNorm normalized name: COPD pharmacologic substance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacologic agents developed to ameliorate or prevent toxicities (specific agents not mentioned)
Trial: 10070911
Drug: High-dose i.v.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose i.v. sodium ferric gluconate complex in sucrose (1.0 g)
Trial: 10070911
Drug: Low-dose i.v.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose i.v. sodium ferric gluconate complex in sucrose (0.5 g)
Trial: 7588508
Drug: 80 g
RxNorm normalized name: PEG-80 GLYCERYL COCOATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 g fat meal
Trial: 7588508
Drug: 20 g
RxNorm normalized name: PEG-20 glyceryl oleate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 g fat meal
Trial: 2188410
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g acetyl salicylic acid as effervescing tablets
Trial: 31948926
Drug: Simvastatin treatment
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simvastatin treatment in HARP-2
Trial: 25122642
Drug: 8 mg
RxNorm normalized name: alloin 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg of intravenous dexamethasone
Trial: 23512440
Drug: 0.9 mg/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9 mg/m2 beloranib
Trial: 20666328
Drug: Dexmedetomidine 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine 1.0 microg x kg(‐1) + ketamine 0.5 mg x kg(‐1) + fentanyl 1.0 microg x kg(‐1) + atropine 0.5 mg (group FNT)
Trial: 20666328
Drug: Dexmedetomidine 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine 1.0 microg x kg(‐1) + ketamine 0.5 mg x kg(‐1) + alfentanil 5.0 microg x kg(‐1) + atropine 0.5 mg (group ALFNT)
Trial: 20666328
Drug: Pethidine 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pethidine 1.0 mg x kg(‐1) + atropine 0.5 mg (group Dolsin)
Trial: 15925053
Drug: Mucoadhesive vaginal
RxNorm normalized name: testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mucoadhesive vaginal gel (MVG, Miphil) 2.5 g daily for the first week and then every 3 days for 5 weeks
Trial: 15925053
Drug: Mucoadhesive vaginal
RxNorm normalized name: testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mucoadhesive vaginal gel (MVG, Miphil)
Trial: 14700450
Drug: Controlled-release formulations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled-release formulations of bupropion, paroxetine, and venlafaxine
Trial: 14700450
Drug: Immediate-release formulations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-release formulations of bupropion, paroxetine, and venlafaxine
Trial: 14700450
Drug: Fluoxetine (controlled-release)
RxNorm normalized name: fluoxetine Delayed Release Oral Capsule
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluoxetine (controlled-release)
Trial: 14700450
Drug: Fluoxetine (immediate-release)
RxNorm normalized name: fluoxetine Delayed Release Oral Capsule
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluoxetine (immediate-release)
Trial: 3523792
Drug: Pirenzepine (PZ)
RxNorm normalized name: pirenzepine
DrugBank: Pirenzepine (DB00670)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pirenzepine (PZ) 50 mg twice daily
Trial: 3523792
Drug: Cimetidine (CM)
RxNorm normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cimetidine (CM) 400 mg twice daily
Trial: 3523792
Drug: Pirenzepine (PZ)
RxNorm normalized name: pirenzepine
DrugBank: Pirenzepine (DB00670)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pirenzepine (PZ) 50 mg at night (maintenance)
Trial: 3523792
Drug: Cimetidine (CM)
RxNorm normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cimetidine (CM) 400 mg at night (maintenance)
Trial: 24664793
Drug: Claims-based measure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Claims-based measure of antipsychotic polypharmacy (90-day concurrent use of ≥2 antipsychotics, allowing for a 32-day gap)
Trial: 18359433
Drug: Relaxation training
RxNorm normalized name: Relax-DS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Relaxation training (single session + daily practice tapes for one month)
Trial: 10660814
Drug: Clonidine monotherapy
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clonidine monotherapy
Trial: 10660814
Drug: Methylphenidate (MPH)
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylphenidate (MPH) monotherapy
Trial: 1565455
Drug: Twice-daily levobunolol
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice-daily levobunolol (0.5%)
Trial: 1565455
Drug: Once-daily levobunolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily levobunolol (0.5%)
Trial: 23697261
Drug: Mometasone furoate
RxNorm normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mometasone furoate (15 days treatment)
Trial: 15042429
Drug: AC+CC genotype
RxNorm normalized name: dengue virus live antigen, CYD serotype 1 / dengue virus live antigen, CYD serotype 2 / dengue virus live antigen, CYD serotype 3 / dengue virus live antigen, CYD serotype 4 Injection [Dengvaxia]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AC+CC genotype of AT1
Trial: 11305827
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg lidocaine plus 10 microg sufentanil
Trial: 11305827
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg lidocaine plus 10 microg sufentanil plus epinephrine 50 microg
Trial: 9029223
Drug: Intravenous glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous glucose (IV) 1.3 g/kg
Trial: 9029223
Drug: Oral glucose
RxNorm normalized name: glucose Oral Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral glucose (PO) 1.3 g/kg
Trial: 7705854
Drug: Trimethoprim 320
RxNorm normalized name: Trimethoprim
DrugBank: Trimethoprim (DB00440)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Trimethoprim 320 mg/sulphamethoxazole 1600 mg by mouth for 2 days (TMPSMX)
Trial: 7705854
Drug: Amoxicillin 3
RxNorm normalized name: amoxicillin 375 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin 3 gm, probenicid 1 gm, and clavulanate 125 mg by mouth once (APC)
Trial: 7705854
Drug: Amoxicillin 3
RxNorm normalized name: amoxicillin 375 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin 3 gm, probenicid 1 gm, and clavulanate 125 mg by mouth once with doxycycline 100 mg BID for 7 days (APC-D)
Trial: 7705854
Drug: Gentamicin 240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gentamicin 240 mg IM once (GENT)
Trial: 7705854
Drug: Ciprofloxacin 250
RxNorm normalized name: ciprofloxacin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin 250 mg by mouth once (CIPRO)
Trial: 3129938
Drug: Low-dose alcohol
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose alcohol consumption (one beverage per day)
Trial: 29417831
Drug: Aquatic exercise
RxNorm normalized name: Mentha aquatica leaf extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aquatic exercise (n=31), 8-week treatment protocol, 16 individual sessions, twice a week
Trial: 25636328
Drug: Genotyping for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Genotyping for CYP2D6 with dosing advice communicated to the treating physician
Trial: 9673299
Drug: 30 microg
RxNorm normalized name: Levonorgestrel 30 microgram oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 microg of OspA vaccine
Trial: 23918037
Drug: Certolizumab pegol
RxNorm normalized name: Certolizumab Pegol
DrugBank: Certolizumab pegol (DB08904)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Certolizumab pegol (CZP) 400 mg every other week (Q2W), reduced to 200 mg Q2W after ≥6 months + Methotrexate (MTX)
Trial: 22454006
Drug: Flexible extended
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flexible extended regimen with MIB (minimum 24, maximum 120 days of continuous tablet intake)
Trial: 22454006
Drug: Conventional 28-day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional 28-day regimen (24 active and four placebo tablets for five cycles)
Trial: 12866946
Drug: Atenolol 50
RxNorm normalized name: atenolol 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol 50 mg test formulation
Trial: 12866946
Drug: Atenolol 50
RxNorm normalized name: atenolol 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol 50 mg reference formulation
Trial: 1828570
Drug: Calcium entry
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium entry blockers (CEB)
Trial: 30585459
Drug: Intravenous anesthesia
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous anesthesia group
Trial: 24439636
Drug: Lavender aromatherapy
RxNorm normalized name: LAVENDER
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lavender aromatherapy (10% concentration inhaled for 5 minutes during 3 hemodialysis sessions)
Trial: 22936194
Drug: Propofol 1
RxNorm normalized name: propofol 10 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol 1 mg/kg/h plus Ketamine 5 µg/kg/min and Remifentanil 0.1 µg/kg/min (GK)
Trial: 22936194
Drug: Propofol 1
RxNorm normalized name: propofol 10 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol 1 mg/kg/h plus Remifentanil 0.25 µg/kg/min (GR)
Trial: 19834700
Drug: 100 mL
RxNorm normalized name: PVC IV Bag 100 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mL of 300 mgI/mL
Trial: 19834700
Drug: 80 mL
RxNorm normalized name: urinary bag 480 mL MISCELL EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mL of 370 mgI/mL
Trial: 19834700
Drug: 60 mL
RxNorm normalized name: Disposable Nurser 60 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mL of 370 mgI/mL followed by a 30‐mL saline flush
Trial: 17393343
Drug: Int3 (intensified
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Int3 (intensified antidiabetic therapy for 3 weeks)
Trial: 17393343
Drug: Int52 (intensified
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Int52 (intensified antidiabetic therapy for 52 weeks)
Trial: 17393343
Drug: Con3 (unchanged
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Con3 (unchanged therapy for 3 weeks)
Trial: 17393343
Drug: Con52 (unchanged
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Con52 (unchanged therapy for 52 weeks)
Trial: 11872998
Drug: Concentration-controlled therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concentration-controlled therapy (zidovudine, lamivudine, and indinavir)